142 related articles for article (PubMed ID: 9213861)
21. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study.
Rademaker M; Cooke ED; Almond NE; Beacham JA; Smith RE; Mant TG; Kirby JD
BMJ; 1989 Mar; 298(6673):561-4. PubMed ID: 2467711
[TBL] [Abstract][Full Text] [Related]
22. MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial.
Chung L; Shapiro L; Fiorentino D; Baron M; Shanahan J; Sule S; Hsu V; Rothfield N; Steen V; Martin RW; Smith E; Mayes M; Simms R; Pope J; Kahaleh B; Csuka ME; Gruber B; Collier D; Sweiss N; Gilbert A; Dechow FJ; Gregory J; Wigley FM
Arthritis Rheum; 2009 Mar; 60(3):870-7. PubMed ID: 19248104
[TBL] [Abstract][Full Text] [Related]
23. Effect of the calcium channel blocker nifedipine on Raynaud's phenomenon. A controlled double blind trial.
Sauza J; Kraus A; González-Amaro R; Alarcón-Segovia D
J Rheumatol; 1984 Jun; 11(3):362-4. PubMed ID: 6376801
[TBL] [Abstract][Full Text] [Related]
24. [Corinfar in the treatment of Raynaud's syndrome in systemic scleroderma (preliminary results)].
Shcherbakov AB; Guseva NG; Mach ES
Ter Arkh; 1985; 57(5):141-4. PubMed ID: 4023933
[TBL] [Abstract][Full Text] [Related]
25. [Calcium antagonists for the treatment of Raynaud's phenomenon].
Müller-Bühl U; Diehm C; Scheuermann W; Mörl H
Dtsch Med Wochenschr; 1983 Nov; 108(47):1795-7. PubMed ID: 6357692
[TBL] [Abstract][Full Text] [Related]
26. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.
Thompson AE; Shea B; Welch V; Fenlon D; Pope JE
Arthritis Rheum; 2001 Aug; 44(8):1841-7. PubMed ID: 11508437
[TBL] [Abstract][Full Text] [Related]
27. Laser Doppler-recorded venoarteriolar reflex in Raynaud's phenomenon.
Stoyneva Z
Auton Neurosci; 2004 Nov; 116(1-2):62-8. PubMed ID: 15556839
[TBL] [Abstract][Full Text] [Related]
28. Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol.
Milio G; Corrado E; Genova C; Amato C; Raimondi F; Almasio PL; Novo S
Rheumatology (Oxford); 2006 Aug; 45(8):999-1004. PubMed ID: 16484290
[TBL] [Abstract][Full Text] [Related]
29. The effectiveness of ketanserin in patients with primary Raynaud's phenomenon. A randomized, double blind, placebo controlled study.
van de Wal HJ; Wijn PF; van Lier HJ; Skotnicki SH
Int Angiol; 1987; 6(3):313-22. PubMed ID: 3329207
[TBL] [Abstract][Full Text] [Related]
30. Nifedipine in the treatment of Raynaud's phenomenon in patients with systemic sclerosis.
Meyrick Thomas RH; Rademaker M; Grimes SM; MacKay A; Kovacs IB; Cook ED; Bowcock SM; Kirby JD
Br J Dermatol; 1987 Aug; 117(2):237-41. PubMed ID: 3307894
[TBL] [Abstract][Full Text] [Related]
31. [Treatment of Raynaud's syndrome with calcium entry blockers].
Shcherbakov AB; Guseva NG; Mach ES
Ter Arkh; 1987; 59(4):89-92. PubMed ID: 3296288
[TBL] [Abstract][Full Text] [Related]
32. Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis.
Thompson AE; Pope JE
Rheumatology (Oxford); 2005 Feb; 44(2):145-50. PubMed ID: 15546967
[TBL] [Abstract][Full Text] [Related]
33. [Treatment of Raynaud's syndrome in systemic connective tissue diseases with calcium antagonists].
Shcherbakov AB
Vutr Boles; 1988; 27(6):55-8. PubMed ID: 3247706
[TBL] [Abstract][Full Text] [Related]
34. Seasonal variation of Raynaud's phenomenon secondary to systemic sclerosis.
Watson HR; Robb R; Belcher G; Belch JJ
J Rheumatol; 1999 Aug; 26(8):1734-7. PubMed ID: 10451070
[TBL] [Abstract][Full Text] [Related]
35. Treatment of Raynaud's phenomenon with nifedipine short-term and long-term effects.
Kallenberg CG; Wouda AA; Kuitert JJ; Tijssen J; Wesseling H
Vasa Suppl; 1987; 18():68-70. PubMed ID: 3299818
[No Abstract] [Full Text] [Related]
36. Controlled trial of nifedipine in the treatment of Raynaud's phenomenon.
Smith CD; McKendry RJ
Lancet; 1982 Dec; 2(8311):1299-301. PubMed ID: 6128596
[TBL] [Abstract][Full Text] [Related]
37. Misoprostol effects on diclofenac-induced cardiorenal changes in salt-sensitive patients with hypertension: the MEDIC Study.
Munger MA; Gardner SF; Ateshkadi A; Rabetoy GM; Barri YM; Stoddard GJ; Cheung AK;
Pharmacotherapy; 2008 Jul; 28(7):834-42. PubMed ID: 18576898
[TBL] [Abstract][Full Text] [Related]
38. Increased circulating platelet-leucocyte complexes in patients with primary Raynaud's phenomenon and Raynaud's phenomenon secondary to systemic sclerosis: a comparative study.
Pamuk GE; Turgut B; Pamuk ON; Vural O; Demir M; Cakir N
Blood Coagul Fibrinolysis; 2007 Jun; 18(4):297-302. PubMed ID: 17473568
[TBL] [Abstract][Full Text] [Related]
39. Laser-Doppler flowmetry in the assessment of "mild" Raynaud's phenomenon and its treatment.
Cesarone MR; Laurora G; Smith SR; Belcaro G
Panminerva Med; 1990; 32(4):151-4. PubMed ID: 2090987
[TBL] [Abstract][Full Text] [Related]
40. [Oral N-acetylcysteine in the treatment of Raynaud's phenomenon secondary to systemic sclerosis: a randomized, double-blind, placebo-controlled clinical trial].
Correa MJ; Mariz HA; Andrade LE; Kayser C
Rev Bras Reumatol; 2014; 54(6):452-8. PubMed ID: 25458027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
